Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

59 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-28

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase III, multicenter, open-label study of RI-002 administered as an intravenous infusion of RI-002 (IGIV) every 21 or 28 days in approximately 60 subjects with Primary Immunodeficiency Diseases (PIDD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

NCT00168012

Agammaglobulinemia IgG Deficiency Common Variable Immunodeficiency

COMPLETED PHASE3

Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

NCT00405184

Primary Immune Deficiency (PID)

COMPLETED PHASE3

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

NCT01406470

Immunologic Deficiency Syndrome

COMPLETED PHASE3

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

NCT00680446

Primary Immune Deficiency

COMPLETED PHASE3

Subcutaneous Ig NextGen 16% in PID Patients

NCT00391131

Primary Immunodeficiency (PID)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary immunodeficiency diseases (PIDDs) are genetically determined disorders of the immune system resulting in greatly enhanced susceptibility to infectious disease, autoimmunity and malignancy. As most subjects with PIDDs present with infections, the differential diagnosis and initial investigations for an underlying immune defect are typically guided by the clinical presentation. In subjects with PIDDs, individual infections are not necessarily more severe than those that occur in a normal host. Rather, the clinical features suggestive of an immune defect may be the recurring and/or chronic nature of infections with common pathogens that may result in end organ damage, such as bronchiectasis. Several immune globulin products have already been approved by the FDA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Immune Deficiency Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RI-002 Treatment

Drug: RI-002 Dose: 300-800 mg/kg infusion Frequency: Once every 3 to 4 Weeks

Group Type EXPERIMENTAL

RI-002

Intervention Type BIOLOGICAL

Immune Globulin Intravenous (IGIV)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RI-002

Immune Globulin Intravenous (IGIV)

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Immune Globulin (Human)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be eligible to participate in this study, the subjects must meet the following criteria:

1. Signed a written informed consent or a specific assent form for minors.
2. Have a diagnosis of primary immunodeficiency disease.
3. Be ≥ 2 years and ≤ 75 years.
4. Have body weight ≥ 12 kg at screening.
5. Have been receiving IGIV at a dose that has not been changed by \>50% of the mean dose on a mg/kg basis for at least 3 months prior to study entry and have maintained a trough serum Immunoglobulin G (IgG) level ≥ 500 mg/dL on the previous 2 assessments prior to receiving RI 002. The trough level must be at least 300 mg/dL above the pre-treatment serum IgG level.
6. For female subjects, be of non-childbearing potential or have a negative pregnancy test prior to study start and be deemed not at risk of becoming pregnant by adherence to a reliable contraceptive method for the duration of the study.

Exclusion Criteria

Subjects must be excluded if they meet any of the following criteria:

1. Have a known hypersensitivity to immunoglobulin or any excipient in RI-002.
2. Have a history of a severe anaphylactic or anaphylactoid reaction to blood or any blood-derived product.
3. Have a specific Immunoglobulin A (IgA) deficiency, history of allergic reaction to products containing IgA or has demonstrable antibodies to IgA.
4. Have uncompensated hemodynamically significant congenital or other heart disease.
5. Have a medical condition that is known to cause secondary immune deficiency.
6. Have a significant T-cell deficiency or deficiency of granulocyte number or function.
7. Have significant renal impairment or have a history of acute renal failure.
8. Have abnormal liver function.
9. Be receiving chronic anti-coagulation therapy.
10. Have a history of deep vein thrombosis (DVT), thrombotic or thrombo-embolic event, or are at increased risk for thrombotic events.
11. Current daily use of the following medications:

* corticosteroids (\> 7.5 mg (or equivalent dose on a mg/kg basis) of prednisone equivalent per day for \> 30 days)
* immunomodulatory drugs
* immunosuppressive drugs (excluding topical pimecrolimus (Elidel) and tacrolimus (Protopic))
12. Administration of a hyperimmune or specialty high titer immunoglobulin product.
13. Have uncontrollable arterial hypertension.
14. Have a history of hemolysis or positive Coombs test while undergoing treatment with IGIV therapy.
15. Be morbidly obese as indicated by a Body Mass Index (BMI) ≥ 40
16. Have received any blood product (other than Immunoglobulin G) within 3 months prior to screening.
17. Have received any Respiratory Syncytial Virus (RSV) specific products, including palivizumab (Synagis®) within 3 months prior to screening.
18. Have abused alcohol, opiates, psychotropic agents, or other chemicals or drugs within the past 12 months.
19. Have any condition or abnormal laboratory assessment judged by the investigator to preclude participation in the study.
20. Are currently pregnant or nursing.
21. Have hepatitis A, B, or C.

Minimum Eligible Age

2 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No